REGENXBIO Inc. RGNX
7.40
0.16
2.21%
as of 25 Sep
- Market cap
- $487.8M
- P/E
- 0.0×
Follow RGNX
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(76.88%) | (107.00%) | (196.43%) | (137.63%) | |
| (34.07%) | (42.19%) | (69.65%) | (40.60%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(56.50%) | (72.33%) | (133.47%) | (77.95%) | |
Average Days of Receivables |
57.35 | 56.49 | 41.72 | 223.32 | |
Free Cash Flow per Share |
(2.06) | (2.45) | (4.51) | (4.73) | |
Free Cash Flow |
(106.28) | (126.38) | (236.40) | (249.67) | |
Capital Expenditures |
(2.98) | (2.41) | (2.62) | (2.99) | |
Piotroski F-Score |
4.00 | 4.00 | 1.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(23.71%) | (37.25%) | (136.26%) | (138.97%) | |
Accounts Receivable Turnover |
6.59 | 7.28 | 6.22 | 2.75 | |
Accounts Payable Turnover |
0.99 | 0.92 | 1.39 | 1.28 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
392.84 | 384.06 | 277.08 | 238.73 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
135.80% | 133.95% | 264.80% | 131.32% | |
Selling, General and Administrative Expense of Revenue |
49.92% | 48.62% | 95.45% | 49.03% | |
Share Based Compensation of Revenue |
22.15% | 20.28% | 39.45% | 20.08% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.58 | 0.64 | 0.81 | 1.26 | |
Depreciation/Fixed assets |
0.15 | 0.15 | 0.15 | 0.17 | |
Capex/Depreciation |
(0.19) | (0.15) | (0.17) | (0.18) | |
Revenue per Share |
3.12 | 3.30 | 1.68 | 3.30 | |
Operating CF per Share |
(2.00) | (2.40) | (4.46) | (4.67) | |
Capex per Share |
(0.06) | (0.05) | (0.05) | (0.06) | |
Capex to Sales |
0.02 | 0.01 | 0.03 | 0.02 | |
Net Profit Margin |
(110.29%) | (113.75%) | (330.23%) | (112.58%) |
Columns are period end dates